HALO vs. EXEL, RLAY, NVAX, ALLO, FATE, ADPT, RGEN, KOD, NBIX, and CRSP
Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Exelixis (EXEL), Relay Therapeutics (RLAY), Novavax (NVAX), Allogene Therapeutics (ALLO), Fate Therapeutics (FATE), Adaptive Biotechnologies (ADPT), Repligen (RGEN), Kodiak Sciences (KOD), Neurocrine Biosciences (NBIX), and CRISPR Therapeutics (CRSP). These companies are all part of the "biological products, except diagnostic" industry.
Exelixis (NASDAQ:EXEL) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership.
Exelixis presently has a consensus target price of $26.29, indicating a potential upside of 12.09%. Halozyme Therapeutics has a consensus target price of $53.29, indicating a potential upside of 38.40%. Given Exelixis' stronger consensus rating and higher probable upside, analysts clearly believe Halozyme Therapeutics is more favorable than Exelixis.
Halozyme Therapeutics has lower revenue, but higher earnings than Exelixis. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
Exelixis has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
Exelixis received 75 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 69.02% of users gave Halozyme Therapeutics an outperform vote while only 68.09% of users gave Exelixis an outperform vote.
85.3% of Exelixis shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.9% of Exelixis shares are held by insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Halozyme Therapeutics has a net margin of 33.96% compared to Halozyme Therapeutics' net margin of 11.35%. Exelixis' return on equity of 248.20% beat Halozyme Therapeutics' return on equity.
In the previous week, Halozyme Therapeutics had 15 more articles in the media than Exelixis. MarketBeat recorded 20 mentions for Halozyme Therapeutics and 5 mentions for Exelixis. Exelixis' average media sentiment score of 1.07 beat Halozyme Therapeutics' score of 0.21 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.
Summary
Halozyme Therapeutics beats Exelixis on 13 of the 18 factors compared between the two stocks.
Get Halozyme Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Halozyme Therapeutics Competitors List
Related Companies and Tools
